Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Simone Claudiani

Showing results (31-40 of 35) with videos related to

Pageof 4
Sort By:
You have reached the last page of results.This site can display upto 35 results.
Nature Communications|November 14, 2022
Third primary SARS-CoV-2 mRNA vaccines enhance antibody responses in most patients with haematological malignanciesLucy B Cook, Gillian O'Dell, Eleni Vourvou, et al.
Cancers|October 13, 2021
Carfilzomib Enhances the Suppressive Effect of Ruxolitinib in MyelofibrosisSimone Claudiani, Clinton C Mason, Dragana Milojkovic, et al.
Leukemia|September 19, 2024
Impact of BCR::ABL1 single nucleotide variants on asciminib efficacyAndrew J Innes, Chloe Hayden, Victoria Orovboni, et al.
British Journal of Haematology|May 3, 2026
Real-world treatment patterns and outcomes in accelerated and blast-phase myeloproliferative neoplasms: Insights from a large multi-centre cohort analysis in the United KingdomAlexandros Rampotas, Gabriel Naylor-Layland, Clare Brown, et al.
Annals of Hematology|November 18, 2018
Safety and efficacy of bosutinib in fourth-line therapy of chronic myeloid leukemia patientsValentín García-Gutiérrez, Dragana Milojkovic, Juan Carlos Hernandez-Boluda, et al.
Pageof 4

Showing results (31-40 of 35) with videos related to

Sort By:
Pageof 4
You have reached the last page of results.This site can display upto 35 results.
Nature Communications|November 14, 2022
Third primary SARS-CoV-2 mRNA vaccines enhance antibody responses in most patients with haematological malignanciesLucy B Cook, Gillian O'Dell, Eleni Vourvou, et al.
Cancers|October 13, 2021
Carfilzomib Enhances the Suppressive Effect of Ruxolitinib in MyelofibrosisSimone Claudiani, Clinton C Mason, Dragana Milojkovic, et al.
Leukemia|September 19, 2024
Impact of BCR::ABL1 single nucleotide variants on asciminib efficacyAndrew J Innes, Chloe Hayden, Victoria Orovboni, et al.
British Journal of Haematology|May 3, 2026
Real-world treatment patterns and outcomes in accelerated and blast-phase myeloproliferative neoplasms: Insights from a large multi-centre cohort analysis in the United KingdomAlexandros Rampotas, Gabriel Naylor-Layland, Clare Brown, et al.
Annals of Hematology|November 18, 2018
Safety and efficacy of bosutinib in fourth-line therapy of chronic myeloid leukemia patientsValentín García-Gutiérrez, Dragana Milojkovic, Juan Carlos Hernandez-Boluda, et al.
Pageof 4